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ABSTRACT
Background: Depression has been linked to poorer asthma control in asthmatic patients. Although the Japa-
nese version of the Asthma Control Test (ACT-J) is frequently used as a simple, practical evaluation tool in
clinical care settings in Japan, knowledge regarding its efficacy for assessing asthma control in asthmatic pa-
tients with depression is limited. Thus, we retrospectively investigated cut-off values of the ACT-J for well-
controlled asthma, and explored depression’s influence on the test with a questionnaire survey.
Methods: Data were analyzed on 1,962 adult asthmatic patients who had completed both the ACT-J and the
Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) in 2008 questionnaire survey conducted by
the Niigata Asthma Treatment Study Group. Patients were classified into low (LD: J-PHQ-9 score of 0-4) or
high depression (HD: J-PHQ-9 score of 5-27) groups. In both groups, the efficacy of the ACT-J was confirmed.
We then compared the optimal cut-off points for uncontrolled asthma in both groups by performing a receiver
operating characteristic (ROC) analysis, using the original classification referred to the GINA classification as
the “true” classification.
Results: Cronbach’s alpha in the LD and HD group was 0.808 and 0.740 respectively. In both groups, the sub-
group with existence of work absenteeism or frequent attacks during the previous 12 months scored lower on
the ACT-J. The area under the curve and optimal cut-off point for patients with LD and HD were 0.821 and
0.846, and 23 and 20 respectively.
Conclusions: The efficacy of the ACT-J was confirmed in depressive patients with asthma. Because asthma
control as evaluated with the ACT-J can be worse than actual control under depressive states, physicians
should also pay attention to a patient’s depressive state at evaluation. Further investigations focus on the asso-
ciation between the ACT-J and depression are required.
KEY WORDS
ACT, asthma, control, depression, PHQ-9
INTRODUCTION
The Global Initiative for Asthma (GINA) guidelines
have promoted remarkable improvements in the
management of asthma, together with several other
guidelines for effective asthma management based on
these.1-3 Because of its high prevalence,4-6 general
physicians play a central role in managing asthma.
According to these guidelines―including those of
the Japanese Society of Allergology (JSA)―a pulmo-
nary function tests are usually required to manage
asthma in addition to identifying symptoms patients
have, such as coughing and dyspnea. However, gen-
eral physicians may find it difficult to perform these
tests.3,7-9 The Asthma Control Test (ACT) was re-
cently developed to assess asthma control,10 in which
a pulmonary function tests are not needed. Research
on the ACT has reported it to be an excellent tool for
the evaluation of asthma control,11-13 and has identi-
fied a cut-off score for controlled or uncontrolled
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asthma of 19 or 20 on the test.14-17 The efficacy of the
Japanese version of the ACT (ACT-J), which has been
introduced in Japan, has also been verified.18-20 How-
ever, few studies have examined the ACT-J’s optimal
cut-off score for predicting well-controlled or uncon-
trolled asthma. In a previous study that we con-
ducted, we identified a cut-off score of no lower than
22 on the ACT-J for predicting well-controlled asthma
with high specificity and sensitivity.21,22 From these
results, we speculated that a specific cut-off score
could not be fixed, but was variable under different
conditions, including ethnicity and complicated dis-
eases.
On the other hand, psychological factors have been
found to be associated with asthma.23,24 Among
these, depression plays an influential role because
health-related quality of life, one of the most impor-
tant goals of asthma management, is reduced by the
onset of depression.25,26 In secondary care popula-
tions, up to 50% of patients with asthma have been re-
ported to have clinically significant depressive symp-
toms, and over a third of asthmatic outpatients have
been known to have a major depressive episode.27-32
Large-scale studies identified an age- and sex-
adjusted odds ratio of 1.6 for depression in individu-
als with asthma compared to those without.33-35 The
Patient Health Questionnaire-9 (PHQ-9), consisting of
nine items related to depression alone, was devel-
oped for evaluating depressive states in actual clinical
care. Its sensitivity and specificity have been shown
to be high compared with other questionnaires for
depression.36 A higher score on the PHQ-9 indicates
more severe depression. In 2007, the validity of the
Japanese version of the PHQ-9 (J-PHQ-9) was con-
firmed by Muramatsu et al..37
The Niigata Asthma Treatment Study Group has
been conducting a regular questionnaire survey of
problems related to asthma management since 1998.
Analyzing survey data from 2008, we reported that
depression might worsen asthma control as results
indicated that patients with higher PHQ-9 scores also
had lower ACT-J scores.38 There are two possible ex-
planations for our findings. The first is that depres-
sion actually influences control of asthma. The sec-
ond is that asthmatic patients with depression may
express lower scores on the measure (the ACT-J)
than those without depression even when both have
the same actual levels of control; depression may al-
ter the optimal cut-off score of the ACT-J for predict-
ing controlled or uncontrolled asthma. In this study,
we explored the influence of depression on the cut-off
score of the ACT-J for controlled or uncontrolled
asthma, referring to the GINA guidelines for our defi-
nition of the construct and using data drawn from our
2008 questionnaire survey.
METHODS
Participation in the study was open to all medical in-
stitutions in the Niigata Prefecture if they intended to
join the Niigata Asthma Treatment Study Group. This
study was performed with the approval of the Ethics
Committee at the School of Medicine of Niigata Uni-
versity (#701), Japan, or at participating institutions,
in accordance with the Ethical Principles for Medical
Research Involving Human Subjects (Declaration of
Helsinki). Written informed consent was obtained
from all of the patients. The study involved 28 large
hospitals (200 beds or more), 14 small hospitals
(fewer than 200 beds), and 62 clinics (no beds). We
received 3,146 responses from 5,260 questionnaires
(response rate: 59.8%). The content of the question-
naire was written in Japanese, and the questionnaire
survey was performed over 2 months from Septem-
ber to October 2008. Subjects were adult patients
(aged 16 years or more) with bronchial asthma who
regularly visited the participating institutions for
asthma management (typically once or twice per
month). The recruited patients were asked to com-
plete the questionnaire by themselves. Individual pa-
tients were therefore expected to understand techni-
cal terms such as “attack” in the questionnaire. This
questionnaire also included the ACT-J.
In addition to the ACT-J, patients were asked about
their peak flow meter (PEFM) use, smoking status,
and incidence of asthma attacks during the 2 weeks
prior. The questionnaire also included items on
asthma-related symptoms over the 2-week period be-
fore completing the questionnaire, including those re-
garding coughs and sputum in the morning and at
night, and sleep disturbances. The patients were also
asked a series of questions to evaluate their condition
during the year before completing the ACT-J ques-
tionnaire. In addition to monitoring the completion of
the questionnaire by the patient, physicians were
asked to supply details on current treatment, medica-
tion used for primary control, type of asthma (atopic
or non-atopic) as indicated by total serum IgE or de-
tection of a specific IgE for allergens, and severity of
asthma in accordance with the JSA guideline, Asthma
Prevention and Management Guideline 2006, Japan.
We measured depressive symptoms using the
nine-item J-PHQ-9 which was developed from the
original PRIME-MD PQ (Patient Questionnaire),39,40
and in which the response categories were dichoto-
mous (“yes” or “no”).39 The J-PHQ-9 can be used to
measure the severity of depressive symptoms, with
probable scores on the questionnaire ranging from 0
to 27. Score ranges for levels of depressive symptoms
were as follows: minimal (0-4), mild (5-9), moderate
(10-14), moderate-severe (15-19), and severe (20-27).
In this study, we assessed the J-PHQ-9 scores of par-
ticipants according to the original PRIME-MD Patient
Health Questionnaire (PQ) and divided the scores
into the following two groups: the low-grade depres-
sive group (LD: J-PHQ-9 score = 0-4) and high-grade
depressive group (HD: J-PHQ-9 score = 5-27).
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Based on the questionnaire survey mentioned
above, each patient was retrospectively evaluated
with respect to the following criteria: (1) the fre-
quency of asthma attacks during the previous 2
weeks before completing the questionnaire, classified
as “none,” “1-2 timesweek,” “3-4 timesweek,” or “5-
7 timesweek”; (2) the appearance of morning and
nocturnal symptoms related to asthma during the
previous 2 weeks before completing the question-
naire, classified as “symptom (-)” or “symptom (+)”;
(3) the existence of sleep disturbances during the
past 2 weeks before completing the questionnaire,
classified as “sleep disturbance (-)” or “sleep distur-
bance (+)”; (4) the existence of work absenteeism
during the year before completing the questionnaire,
classified as “absent” or “present”; (5) frequency of
asthma attacks during the year before completing the
questionnaire, classified as “few” “seasonal” or “per-
sistent”; and (6) the severity of asthma based on the
2006 JSA guideline, classified as Step 1, 2, 3, or 4. Pa-
tients were divided into groups based on their re-
sponses to each category.
Analyses of the influence of depression on the
ACT-J were then performed with the following proce-
dure. First, we divided the patients into 2 groups, LD
and HD, according to their J-PHQ-9 scores. Cron-
bach’s alpha, an excellent indicator of internal consis-
tency in questionnaires ranged from 0.000 to 1.000,
was calculated for both groups. The questionnaire is
usually estimated to be reliable when it is beyond
0.700. Second, comparisons of the ACT-J scores were
performed among patients with different asthma con-
trol levels in LD and HD groups. These steps were
performed to determine the reliability and validity of
the ACT-J in assessing asthma control in each study
group. Because the original aim of conducting the
ACT-J in the 2008 survey was not to evaluate the
test’s efficacy but to assess patients’ asthma control,
there was inadequate information on exact criteria for
establishing asthma control provided by GINA 2006.
Thus, status of asthma control, as referred by GINA
2006 guidelines, was determined using criteria (1),
(2), and (3) mentioned above: (A) controlled asthma,
in which a patient had no asthma attacks, no morning
or nocturnal symptoms related to asthma, and no
sleep disturbances during the 2 weeks before answer-
ing the questionnaire; (B) uncontrolled asthma, in
which a patient had asthma attacks, symptoms that
included sleep disturbances, or morning or nocturnal
symptoms related to asthma during the 2 weeks be-
fore completing the questionnaire. Employing this
definition, the screening performance of the ACT-J
was analyzed to ascertain depression’s influence on
the ACT-J scores of patients with equivalent control.
Results for continuous variables, except ACT-J and
J-PHQ-9 scores, were expressed as arithmetic means
and standard deviations. ACT-J and J-PHQ-9 scores
were expressed as median values and interquartile
ranges (IQRs). Intergroup differences in terms of
continuous variables were evaluated using the
Kruskal-Wallis test and Mann-Whitney U test with
Bonferroni correction. All statistical analyses were
performed using the statistical software JMPⓇ 10
(SAS Institute; Cary, NC, USA) and SPSS. For all sta-
tistical analyses, a P-value of <0.05 was considered
significant.
RESULTS
DEMOGRAPHIC AND CLINICAL CHARACTERIS-
TICS OF PATIENTS
Of the 3,146 asthmatic patients who answered the
questionnaire, 1,962 also completed the ACT-J and J-
PHQ-9. Demographic and clinical characteristics of
the patients are shown in Table 1. The age (years,
mean ± SD), gender (%, malefemale), disease dura-
tion (years, mean ± SD), disease type (%, atopicnon-
atopic), smoking status (%, non-smokerex-smoker
current-smoker), and peak-flow meter use rate (%)
were 54.8 ± 17.2, 42.755.9, 14.3 ± 13.9, 45.748.7,
51.330.016.5, and 26.9 respectively. Median ACT-J
and PHQ-9 scores [interquartile range (IQR)] were
23 [20-25] and 1 [0-4], respectively. Rates (%) of
asthma attacks, morning symptoms, nocturnal symp-
toms, and sleep disturbances during the previous 2
weeks before the questionnaire were 24.4, 42.4, 30.2,
and 14.1 respectively. The rate of work absenteeism
during the previous 12 months before the question-
naire was 9.5%. The proportions (%) of patients who
qualified their asthma attacks, responding with “per-
sistent attacks”, “seasonal attacks” and “few attacks,”
were 9.8, 36.5 abd 45.0%, respectively. The rates of
use for each type of medication were: >-80% for in-
haled corticosteroids (ICS), >-40% for leukotriene re-
ceptor antagonists (LTRAs), >-40% for oral sustained-
released theophylline (OSRT), 4.9% for oral corti-
costeroids (OCS), and 38.9% for long-acting beta ago-
nists (LABAs). The rates (%) of asthma severity
(Steps 1 through 4) were 24.2, 39.1, 26.6, and 5.2 re-
spectively. Meanwhile, the rates of “controlled” and
“uncontrolled” asthma, as defined by our original
classification, were 49.3 and 50.7 respectively.
EFFICACY OF THE ACT-J FOR ASSESSING
ASTHMA CONTROL IN LOW- AND HIGH-GRADE
DEPRESSIVE GROUPS
Cronbach’s alpha in the LD and HD groups was 0.808
and 0.740 respectively. In both groups, ACT-J scores
were significantly lower among patients who had ex-
perienced work absenteeism due to asthma exacerba-
tions during the year before the questionnaire than
those who had not (Table 2A, B). Furthermore, the
ACT-J scores of patients with seasonal and persistent
attacks were significantly lower than those of patients
who experienced few attacks. Patients with persistent
attacks scored significantly lower on the test than
those with seasonal attacks (Table 3A, B).
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Table　1　Demographic and clinical characteristics
Cases 1962
Age (years, mean ± SD) 54.8 ± 17.2
Gender (%, male/female) 42.7/55.9
Disease duration (years, mean ± SD) 14.3 ± 13.9
Disease type (%, atopic/non-atopic) 45.7/48.7
Smoking status (%, non-smoker/ex-smoker/current smoker) 51.3/30.0/16.5
Peak-fl ow meter use rate (%) 26.9
ACT-J score (median [IQR]) 23 [20-25]
J-PHQ-9 score (median [IQR]) 1 [0-4]
Attack rate during the previous 2 weeks before completing the questionnaire (%) 24.4
Morning symptom rate during the previous 2 weeks before completing the questionnaire (%) 42.4
Nocturnal rate during the previous 2 weeks before completing the questionnaire (%) 30.2
Sleep disturbance rate in the previous 2 weeks before completing the questionnaire (%) 14.1
Work absenteeism rate during the previous year before completing the questionnaire (%)  9.5
Frequency of asthma attacks during the previous year before completing the questionnaire
 (%, frequent/seasonal/few)
9.8/36.7/45.0
ICS use rate (%) 86.4
LTRA use rate (%) 42.6
OSRT use rate (%) 43.4
OCS use rate (%)  4.9
LABA use rate (%) 38.9
Severity of asthma based on the 2006 JSA guideline (%, Step 1/2/3/4) 24.2/39.1/26.6/5.2
“Controlled” asthma rate (%) 49.3
“Uncontrolled” asthma rate (%) 50.7
ACT-J, the Asthma Control Test, Japanese Version; J-PHQ-9, the Japanese version of the Patient Health Questionnaire-9; IQR, inter-
quartile range; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist; OSRT, oral sustained-release theophylline; OCS, oral 
corticosteroid; LABA, long-acting beta agonist. 
 “Controlled” asthma and “uncontrolled” asthma are defi ned according to our original classifi cations.
Table　2A　Comparison of ACT-J scores with regard to 
work absenteeism during the year before completing the 
questionnaire (LD group)
None Existence of work absenteeism 
Number of patients 1400 114
ACT-J score
(median [IQR])
24
[21-25]
21
[18-24]*
Table　2B　Comparison of ACT-J scores with regard to 
work absenteeism during the year before completing the 
questionnaire (HD group) 
None Existence of work absenteeism 
Number of patients 295 72
ACT-J score
(median [IQR])
22
[19-24]
18
[13-21]*
ACT-J, the Asthma Control Test, Japanese Version; IQR, inter-
quartile range. *p < 0.0001.
Table　3A　Comparison of ACT-J scores among patients 
with different asthma attack frequencies during the year be-
fore completing the questionnaire (LD group) 
Few 
attacks
Seasonal 
attacks
Persistent 
attacks
Number of patients 757 571 121
ACT-J score
(median [IQR])
24 
[23-25]
22 
[20-24]*
19
 [16-21]*, **
Table　3B　Comparison of ACT-J scores among patients 
with different asthma attack frequencies during the year be-
fore completing the questionnaire (HD group) 
Few 
attacks
Seasonal 
attacks
Persistent 
attacks
Number of patients 126 150 72
ACT-J score
(median [IQR])
23.5
[22-25]
21
[16-23]*
16.5
[11-19]*, **
ACT-J, the Asthma Control Test, Japanese Version; IQR, inter-
quartile range. *p < 0.0005 vs. few; **p < 0.0005 vs. seasonal.
Effects of Depression on the ACT-J
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Table　4A　Screening performance of the ACT-J for LD group at different cut-off points 
ACT-J score/
cut-off point Sensitivity, % Specifi city, %
Positive predic-
tive value, %
Negative predic-
tive value, % Youden index
Area under 
the curve
15 10.69 99.40 94.04 55.82 0.101 0.551
16 13.94 99.28 94.49 56.70 0.132 0.566
17 18.81 98.93 93.91 58.04 0.177 0.589
18 23.82 98.57 93.61 59.75 0.224 0.612
19 32.61 97.97 93.41 62.27 0.306 0.653
20 44.65 95.71 90.16 66.25 0.446 0.702
21 54.67 92.01 82.77 69.73 0.467 0.733
22 65.09 83.67 77.83 73.12 0.488 0.744
23 78.35 73.60 72.28 79.40 0.519 0.760
24 90.26 44.34 58.81 83.78 0.346 0.673
Table　4B　Screening performance of the ACT-J for HD group at different cut-off points
ACT-J score/
cut-off point Sensitivity, % Specifi city, %
Positive predic-
tive value, %
Negative predic-
tive value, % Youden index
Area under 
the curve
18 43.19 99.21 99.10 46.32 0.424 0.712
19 52.14 94.49 95.03 49.38 0.466 0.733
20 61.09 92.13 94.01 53.91 0.532 0.766
21 70.43 82.20 88.29 57.54 0.515 0.763
22 78.21 67.72 83.05 60.56 0.459 0.730
23 89.88 59.06 81.62 74.25 0.489 0.745
24 95.33 36.22 75.15 79.31 0.316 0.658
SCREENING ACCURACY AND DETERMINATION
OF OPTIMAL ACT-J CUT-OFF POINT
The accuracy of the ACT-J in screening for uncon-
trolled asthma in the LD group is summarized in Ta-
ble 4A, where the ACT-J scores represent different
proposed cut-off points. Cut-off points <14 yielded
poor ACT-J classification accuracy and were therefore
dismissed. A score of 23, however, saw the Youden
index peak at 0.519, the maximum. Consequently, we
used an ACT-J score of 23 as the optimal cut-off point
for predicting uncontrolled asthma in the LD group.
As seen from the ROC curve, a cut-off point of 23 rep-
resented the point closest to the top left corner; the
area under the curve (AUC) was 0.821 (Fig. 1A).
The performance of the ACT-J in screening for un-
controlled asthma among patients in the HD group is
summarized in Table 4B, where the ACT-J scores
represent different proposed cut-off points. Cut-off
points <10 yielded poor ACT-J classification accuracy
and were therefore dismissed. A score of 20 instead
saw the Youden index reach a maximum of 0.532.
Therefore, we used an ACT-J score of 20 as the opti-
mal cut-off point for predicting uncontrolled asthma
in the HD group. As Figure 1B illustrates, a cut-off
point of 20 represented the point closest to the top
left corner of the ROC curve, and the AUC was 0.846.
DISCUSSION
We have previously reported that the cut-off score of
the ACT-J for GINA-defined asthma control differed
from those for other populations.22 This indicates the
probability that the cut-off may be partially influenced
by a variety of factors, including depression. The aim
of this study was to investigate the influence of de-
pression on the ACT-J, especially on its cut-off score,
using a questionnaire survey.
To achieve this aim, it was necessary to confirm
the efficacy of the ACT-J for use with asthmatic pa-
tients who not only had low-grade but also high-grade
depression. As mentioned before, the test’s Cron-
bach’s alpha was computed for LD and HD groups of
participants and found to be beyond 0.700 in both in-
stances. In both groups, as well, the ACT-J scores of
subgroups that we had expected to be low, such as
those of patients with persistent asthmatic symptoms,
were actually lower than for patients in opposite sub-
groups whose scores we had anticipated would be
high (Table 2A, B, 3A, B). These results clearly show
that survey data obtained with the ACT-J on both LD
and HD groups had acceptable reliability and validity.
Additionally, the ROC curves of the ACT-J generated
for both groups (Fig. 1A, B) identified a lower optimal
cut-off score for the HD group than for the LD group.
This suggests that an asthmatic patient can be evalu-
ated as having worse asthma control with the ACT-J
when in a more depressive state. In managing asthma
in depressive patients, more objective methods for
evaluating asthma control, such as peak-flow meter
Toyama M et al.
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Fig.　1A　ROC curve of the ACT-J score for assessing un-
controlled asthma in LD group. The area under the curve 
(AUC) was 0.821 (95% CI: 0.801-0.843), and the optimal 
cut-off point was 23.
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Fig.　1B　ROC curve of the ACT-J score for assessing un-
controlled asthma in HD group. The area under the curve 
(AUC) was 0.846 (95% CI: 0.807-0.885), and the optimal 
cut-off point was 20.
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use, are needed. Some clinicians are naturally likely
to realize the effects of depressive states on asthma
control due to their vast experience in managing the
condition in their patients. However, more objective
data regarding the evaluation of asthma control in de-
pressive patients using the ACT were not available
until now. Our report is thought to be the first to ad-
dress this point with regard to asthma control screen-
ing.
The reason why ACT-J scores are lower in depres-
sive patients is partly because an objective measure
of asthma control, such as a pulmonary function test,
is excluded from the ACT-J. In our previous study, we
speculated that differences in the ACT’s optimal cut-
off scores for Japanese and non-Japanese patients
could stem from a difference in how symptoms of
asthma are perceived and expressed.22 The intensity
of dyspnea as experienced by individuals with asthma
does not correlate well with their degrees of airway
obstruction as determined by spirometry.41,42 While
patients with stable asthma always experience dysp-
nea after inhalation of a bronchoconstrictive agent,
the degree of dyspnea associated with any fixed de-
cline (e.g., 20%) in the forced expiratory volume in 1
second during peak expiratory flow varies widely.43
Somatosensory amplification has recently been intro-
duced as a probable explanation for the dissociation
between subjective and objective symptoms in vari-
ous diseases.44,45 Somatosensory amplification has
been reported as playing an important role in patients
with asthma.46 Further investigation, such as
depression-dependent differences in somatosensory
amplification, might be required to explain the differ-
ent cut-off points of the ACT-J.
There were several limitations in this study. The
first pertained to the definition of asthma control used
in the study. The definition of true asthma control
used for generating ROC curves for analyses was
based on different items measuring asthma control in
the ACT-J and not entirely on the GINA guidelines.
Therefore, the absolute value of the cut-off score
demonstrated in the present study was insufficient
with regard to GINA-defined control of asthma. An
important and meaningful finding, however, was the
existence of a significant difference in optimal cut-off
points between LD and HD groups of patients. The
second limitation was the study’s use of the J-PHQ-9.
Although the questionnaire is a useful screening tool
for depressive disorder, the study population may
have also comprised patients who had mood disor-
ders other than depression (e.g., anxiety or adjust-
ment disorders) and those who could not be diag-
nosed as having depression according to DSM-IV cri-
teria, usually used by trained psychologists, but who
were mildly depressed. Further confirmation of our
results using definition criteria based entirely on
GINA 2006 guidelines and other evaluation methods
for depression is necessary.
In summary, we confirmed the efficacy of the ACT-
J for assessing asthma control in asthmatics with
more severe depression. However, the cut-off point of
the ACT-J in more depressive patients was obviously
lower than that in less depressive patients, indicating
that physicians should pay attention to a patient’s de-
pressive state at evaluation. Further research clarify-
ing the relationship between depression and the
ACT-J is needed.
Effects of Depression on the ACT-J
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